244 related articles for article (PubMed ID: 16614231)
1. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
Ettinger DS
Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
4. EGFR-directed therapies to treat non-small-cell lung cancer.
Ho C; Laskin J
Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
[TBL] [Abstract][Full Text] [Related]
5. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
7. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
9. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
Mendelsohn J; Baselga J
J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
[TBL] [Abstract][Full Text] [Related]
10. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
13. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
15. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
16. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
19. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
20. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Thatcher N
Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]